Literature DB >> 16135638

Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine.

Karen A Graham1, Hongbin Gu, Jeffrey A Lieberman, Joyce B Harp, Diana O Perkins.   

Abstract

OBJECTIVE: This study sought to determine if amantadine affects weight gain in psychiatric patients taking olanzapine.
METHOD: Twenty-one adults who had gained at least 5 lb with olanzapine were randomly assigned to receive amantadine (N=12) or placebo (N=9) in addition to olanzapine. The length of time taking olanzapine ranged from 1 to 44 months. Body mass index, psychiatric status, and fasting blood levels were assessed at baseline and 12 weeks.
RESULTS: Significantly fewer subjects taking amantadine gained weight, with a mean change in body mass index of -0.07 kg/m2 for the amantadine group and 1.24 kg/m2 for the placebo group. This effect remained significant when the authors controlled for baseline body mass index and length of olanzapine treatment. No changes in fasting glucose, insulin, leptin, prolactin, and lipid levels were seen. Positive and Negative Syndrome Scale scores remained stable.
CONCLUSIONS: Amantadine induced weight stabilization in subjects taking olanzapine and was well tolerated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16135638     DOI: 10.1176/appi.ajp.162.9.1744

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  27 in total

1.  A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second-generation antipsychotics.

Authors:  Benjamin U Nwosu; Bruce Meltzer; Louise Maranda; Carol Ciccarelli; Daniel Reynolds; Laura Curtis; Jean King; Jean A Frazier; Mary M Lee
Journal:  J Pediatr Endocrinol Metab       Date:  2011       Impact factor: 1.634

Review 2.  Management of antipsychotic-related weight gain.

Authors:  Lawrence Maayan; Christoph U Correll
Journal:  Expert Rev Neurother       Date:  2010-07       Impact factor: 4.618

Review 3.  Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis.

Authors:  Lawrence Maayan; Julia Vakhrusheva; Christoph U Correll
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 4.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

Review 5.  Interventions to reduce weight gain in schizophrenia.

Authors:  G Faulkner; T Cohn; G Remington
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

Review 6.  Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review.

Authors:  Chaya G Bhuvaneswar; Ross J Baldessarini; Veronica L Harsh; Jonathan E Alpert
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

Review 7.  Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.

Authors:  Hua Jin; Jonathan M Meyer; Sunder Mudaliar; Dilip V Jeste
Journal:  Schizophr Res       Date:  2008-01-18       Impact factor: 4.939

Review 8.  Obesity in bipolar disorder: an overview.

Authors:  Susan L McElroy; Paul E Keck
Journal:  Curr Psychiatry Rep       Date:  2012-12       Impact factor: 5.285

9.  Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.

Authors:  Virginia L Stauffer; Ilya Lipkovich; Vicki Poole Hoffmann; Alexandra N Heinloth; H Scott McGregor; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2009-03-28       Impact factor: 3.630

10.  Post-graduate CME.

Authors:  Chittaranjan Andrade
Journal:  Indian J Psychiatry       Date:  2008-04       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.